Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Cognito Therapeutics

WVU Rockefeller Neuroscience Institute and Cognito Therapeutics Launch Brain Health Collaboratory to Accelerate Neurotherapies with AI-powered Research

November 13, 2025

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Presents Clinical Trial Data Highlighting Neuroprotective Potential of Spectris™ in Alzheimer’s Disease at AAIC 2025

July 28, 2025

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics to Present Five Abstracts at AAIC 2025 Highlighting Spectris™ Treatment in Alzheimer’s Disease

July 17, 2025

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Completes Enrollment in HOPE Pivotal Study of Spectris™ AD Therapy for the Treatment of Patients with Alzheimer’s Disease

July 01, 2025

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Announces Non-invasive Neuromodulation Therapy Delays Alzheimer’s Disease Progression

June 11, 2025

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Announces Spectris™ Data Demonstrating Brain Structural Maintenance and Mechanism of Action in Alzheimer’s Disease at AD/PD™ 2025

April 02, 2025

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics to Present New Data on Spectris’™ Impact on Brain Structure in Alzheimer’s Disease at AD/PD 2025

March 25, 2025

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Strengthens Executive Team to Drive Next Phase of Growth and Commercialization

February 12, 2025

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Announces Spectris™ Treatment Demonstrates Myelin and Synaptic Biomarker Changes in Alzheimer’s Disease

February 11, 2025

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Presents Early-Stage Cost-Effectiveness Analysis of Spectris™ Therapy in Alzheimer’s Disease at ISPOR 2024

November 19, 2024

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Announces Spectris™ Treatment Demonstrates 56.4% Reduction in Alzheimer’s Disease Dependence Score with Strong Safety Profile

October 29, 2024

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Publishes Study Demonstrating Structural Brain Preservation in Alzheimer’s Disease in Frontiers in Neurology

October 16, 2024

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics to Present New Data for Spectris™ in Alzheimer’s Disease at CTAD 2024

October 07, 2024

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Appoints Christian Howell as Chief Executive Officer

August 26, 2024

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Announce OVERTURE I Study Demonstrated Significant Time Savings Using Composite Measures of Function and Cognition

July 29, 2024

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Announces Scientific Presentations at the Alzheimer’s Association International Conference 2024

July 08, 2024

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Announces Presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024 Meeting

April 29, 2024

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Announces Spectris™ Demonstrates Durable Effects on Activities of Daily Living in the OVERTURE II Study

April 15, 2024

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Announces Oral Presentation at 2024 American Academy of Neurology (AAN) Annual Meeting

March 13, 2024

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Announces Spectris™ OVERTURE OLE Study Data Supports Potential Disease Modification and Early Treatment in Alzheimer’s Disease

March 11, 2024

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics OVERTURE Clinical Trial in Alzheimer's Disease Published in Frontiers in Neurology

March 06, 2024

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Announces Oral Presentation on Spectris Therapy Open-Label Study Data in Alzheimer’s Disease at AD/PD 2024

February 28, 2024

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Announces First Patient Enrolled in HOPE Biomarker Study

January 23, 2024

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Phase 2 OVERTURE Study MRI Imaging Analysis Published in Journal of Alzheimer’s Disease

December 11, 2023

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics to Present at the 35th Annual Piper Sandler Healthcare Conference

November 13, 2023

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Appoints Christian Howell as Chief Commercial Officer

October 30, 2023

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Presents Phase 2 OVERTURE Study Open-Label Extension Data Showing Safety, Adherence and Durability of Treatment Benefits Over 18 Months

October 24, 2023

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics to Present Phase 2 OVERTURE Study Open-Label Extension Data Showing Safety and Durability of Treatment Benefits Over 18 Months at CTAD 2023

October 18, 2023

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer

October 17, 2023

From Cognito Therapeutics

Via Business Wire

Cognito Therapeutics Presents New MRI Data Showing Non-Invasive Gamma Stimulation Therapy Reduces Brain Atrophy and Myelin Loss in Alzheimer’s Disease

July 17, 2023

From Cognito Therapeutics

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Articles published by Cognito Therapeutics

Resources